BIOBIO-RAD LABORATORIES, INC.

NYSE bio-rad.com


$ 313.73 $ -1.52 (-0.48 %)    

Monday, 26-Aug-2024 15:59:50 EDT
QQQ $ 474.46 $ -4.66 (-0.97 %)
DIA $ 412.48 $ 0.89 (0.22 %)
SPY $ 560.78 $ -1.34 (-0.24 %)
TLT $ 98.13 $ -0.25 (-0.25 %)
GLD $ 232.75 $ 0.74 (0.32 %)
$ 313.42
$ 315.34
$ 313.27 x 100
-- x --
$ 312.65 - $ 317.27
$ 261.59 - $ 406.44
118,045
na
8.74B
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-02-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-16-2024 12-31-2023 10-K
4 10-27-2023 09-30-2023 10-Q
5 08-04-2023 06-30-2023 10-Q
6 05-05-2023 03-31-2023 10-Q
7 02-17-2023 12-31-2022 10-K
8 10-28-2022 09-30-2022 10-Q
9 07-29-2022 06-30-2022 10-Q
10 04-29-2022 03-31-2022 10-Q
11 02-11-2022 12-31-2021 10-K
12 10-29-2021 09-30-2021 10-Q
13 07-30-2021 06-30-2021 10-Q
14 04-30-2021 03-31-2021 10-Q
15 02-16-2021 12-31-2020 10-K
16 10-30-2020 09-30-2020 10-Q
17 07-31-2020 06-30-2020 10-Q
18 05-08-2020 03-31-2020 10-Q
19 03-02-2020 12-31-2019 10-K
20 11-01-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-10-2019 03-31-2019 10-Q
23 04-01-2019 12-31-2018 10-K
24 11-05-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 04-16-2018 12-31-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-01-2017 12-31-2016 10-K
32 11-02-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 02-29-2016 12-31-2015 10-K
36 11-05-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-Q
38 05-06-2015 03-31-2015 10-Q
39 03-02-2015 12-31-2014 10-K
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bio-rad-appoints-jon-divincenzo-as-president-and-chief-operating-officer-effective-september-9-2024-replacing-andy-last-who-is-retiring

Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announ...

 rbc-capital-reiterates-outperform-on-bio-rad-laboratories-maintains-401-price-target

RBC Capital analyst Conor McNamara reiterates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and maintains $401 price tar...

 rbc-capital-maintains-outperform-on-bio-rad-laboratories-lowers-price-target-to-401

RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and lowers the price target f...

 citigroup-maintains-neutral-on-bio-rad-laboratories-raises-price-target-to-350

Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from...

 bio-rad-laboratories-q2-2024-adj-eps-311-beats-201-estimate-sales-6385m-miss-645789m-estimate

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $3.11 per share which beat the analyst consensus estimate of $2....

 sp-500-ends-first-half-shy-of-all-time-highs-here-are-the-leaders-and-laggards--and-5-stocks-that-could-outperform-in-next-6-months

The market's resilient run has made traders cautious of a potential correction, but analysts remain optimistic about its tr...

 jefferies-assumes-bio-rad-laboratories-at-hold-lowers-price-target-of-315

Jefferies assumes Bio-Rad Laboratories (NYSE:BIO) with a Hold rating and lowers Price Target of $315.

 federal-register-reported-fda-announcing-revocation-of-euas-issued-to-bio-rad-laboratories-for-the-bio-rad-sars-cov-2-ddpcr-kit

-Reuters

 ubs-maintains-buy-on-bio-rad-laboratories-lowers-price-target-to-385

UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $420 to $385.

 bio-rad-maintains-its-fy24-financial-outlook

The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 1.0 to 2.5 percent and an estimated ...

 bio-rad-laboratories-q1-2024-adj-eps-229-beats-215-estimate-sales-610820m-miss-619092m-estimate

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $2....

Core News & Articles

- SEC Filing

 96-of-sp-500-stocks-show-upside-potential-vs-street-estimates-which-offers-the-best-opportunity

480 out of 500 S&P 500 companies are trading below analysts' price targets, indicating potential profit opportunities. ...

Core News & Articles

The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more bro...

 bio-rad-laboratories-says-andrew-last-executive-vice-president-and-coo-is-planning-to-retire-by-early-september-of-2024

Last will remain part of Bio-Rad's executive leadership team to ensure a smooth transition while the company conducts a sea...

 citigroup-downgrades-bio-rad-laboratories-to-neutral-lowers-price-target-to-365

Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price targe...

 tech-stocks-ease-on-hot-ppi-yields-rise-microsoft-amazon-snap-5-week-positive-streak-whats-driving-markets-friday

Wall Street takes pause after stronger-than-expected producer inflation report, potentially delaying Fed rate cuts and impactin...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION